Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

April 2021

AGC Biologics Expands Partnership with Rocket Pharmaceuticals

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.
 
Through the expanded partnership, AGC Biologics will bolster the security of supply of Rocket Pharmaceuticals across their entire lentiviral vector (LVV) pipeline, with the manufacture of LVV. 

LVV manufacturing will be performed utilizing both the 48L Cell Factory™ Systems and iCellis® 500 bioreactor platforms. All services are currently being performed at AGC Biologics’ state-of-the-art Center of Excellence for Cell and Gene Therapy services in Milan, Italy.
 
Mark Womack
Chief Business Officer, AGC Biologics

We are honored that Rocket has placed so much trust with us, as demonstrated by our expanding partnership. We’re incredibly proud of the Cell and Gene Therapy services and offerings we’ve brought to market to assist our partners in providing life-changing treatments for those living with rare diseases.

In response to their customer needs and incredible market demand, AGC Biologics has developed a reproducible, high quality and quantity process for the industrial-scale production of LVV. This process allows for the successful scale of LVV manufacture without affecting critical quality attributes (CQA), ultimately improving the commercial viability of LVV-based gene therapies.

Learn more
act

News

There is a lot of news to share about OpenZone. Make sure you're always up-to-date.
all the news